Drug Interactions and Adventures in Polypharmacy

Chapter

Abstract

The use of two or more drugs simultaneously can be perilous, as shown by the ­following case:

Keywords

Lactobacillus Simvastatin Cimetidine Olanzapine Methylphenidate 

References

  1. 1.
    Taylor RB. Medical wisdom and doctoring: the art of 21st century medicine. New York: Springer, 2010. Chapter 5.CrossRefGoogle Scholar
  2. 2.
    Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112–1120.PubMedCrossRefGoogle Scholar
  3. 3.
    Block AJ. Revisiting the Libby Zion case. Chest. 1994;105(4):977.PubMedCrossRefGoogle Scholar

References

  1. 1.
    Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287(3):337–344.PubMedCrossRefGoogle Scholar
  2. 2.
    Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56(3):286–290.PubMedCrossRefGoogle Scholar
  3. 3.
    Lima RE, De Bortoli-Cassiani SH. Potential drug interactions in intensive care patients at a teaching hospital. Rev Lat Am Enfermagem. 2009;17(2):222–227.PubMedCrossRefGoogle Scholar

References

  1. 1.
    Raebel MA, Carroll NM, Andrade SE, et al. Monitoring of drugs with a narrow therapeutic range in ambulatory care. Am J Manag Care. 2006;12(5):268–274.PubMedGoogle Scholar
  2. 2.
    Raoof S, Wollschlager C, Kahn FA. Ciprofloxacin increases serum levels of theophylline. Am J Med. 1987;82(4A):115–118.PubMedGoogle Scholar
  3. 3.
    Adebayo GI, Coker HAB. Cimetidine inhibition of theophylline elimination: the influence of adult age and the time course. Biopharm Drug Dispos. 2006;8(2):149–158.CrossRefGoogle Scholar
  4. 4.
    Renton KW, Gray JD, Hall RI. Decreased elimination of theophylline after influenza vaccination. Can Med Assoc J. 1980;123(4):288–290.PubMedGoogle Scholar

References

  1. 1.
    Dickinson BD, Altman RD, Nielson NH, Sterling ML, for the Council on Scientific Affairs, American Medical Association. Obstet Gyn. 2001;98(5):853–860.CrossRefGoogle Scholar
  2. 2.
    Archer JSM, Archer DF. Oral contraceptives efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol. 2002;46(6):917–923.PubMedCrossRefGoogle Scholar

Reference

  1. 1.
    Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54(10):1516–1523.PubMedCrossRefGoogle Scholar

References

  1. 1.
    Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol. 2008;101(7):1060–1063.PubMedCrossRefGoogle Scholar
  2. 2.
    Rimon G, Sidhu RS, Lauver DA, et al. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc Natl Acad Sci U S A. 2010;107(1):28–33.PubMedCrossRefGoogle Scholar
  3. 3.
    Nainggolan L. Celecoxib could impede effects of low-dose aspirin. Medscape. Available at http://www.medscape.com/viewarticle/714041?src=mpnews&spon=34&uac=95007MG/. Accessed April 12, 2010.

Reference

  1. 1.
    Phelan KM, Mosholdler AD, Lu S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory agents. J Clin Psychiatry. 2003;64(11):1328–1334.PubMedCrossRefGoogle Scholar

Reference

  1. 1.
    Steinhubl SR, Bhatt DL, Brennan DM. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150(6):379–386.PubMedGoogle Scholar

References

  1. 1.
    Information for Healthcare Professionals: Update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). U.S. Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm/. Accessed April 12, 2010.
  2. 2.
    Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256–260.PubMedCrossRefGoogle Scholar
  3. 3.
    Ho PM, Maddox TM, Want L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937–944.PubMedCrossRefGoogle Scholar
  4. 4.
    Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157(1):148.e1–e5.CrossRefGoogle Scholar
  5. 5.
    O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton pump inhibitor: an analysis of two randomized trials. Lancet. 2009;374(9694):989–997.PubMedCrossRefGoogle Scholar
  6. 6.
    Laine L, Henneken C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol. 2009;105(1):34–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitor. Ann Intern Med. 2010;152(6):337–345.PubMedGoogle Scholar
  8. 8.
    Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120(23):2322–2329.PubMedCrossRefGoogle Scholar

References

  1. 1.
    Reeves RR, Mack JE. Possible dangerous interaction of OxyContin and carisoprodol. Am Fam Phys. 2003;67(11):2273.Google Scholar
  2. 2.
    Owens C, Pugmire B, Salness T, et al. Abuse potential of carisoprodol: a retrospective review of Idaho Medicaid pharmacy and medical claims data. Clin Ther. 2007;29(10):2222–2225.PubMedCrossRefGoogle Scholar

References

  1. 1.
    Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010;340:c693. doi: 10.1136/bmj.c693.PubMedCrossRefGoogle Scholar
  2. 2.
    Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009;9(8):576–586.PubMedCrossRefGoogle Scholar
  3. 3.
    Tamoxifen, SSRIs, and breast cancer recurrence. Pharmacology Watch. September, 2009; page 1.Google Scholar
  4. 4.
    Lash TL, Cronin-Fentin D, Ahern TP, et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol. 2010;49(3):305–312.PubMedCrossRefGoogle Scholar

References

  1. 1.
    Jiao X, Velez S, Ringstad J, Eyma V, Miller D, Bleiberg M. Myocardial infarction associated with Adderall XR and alcohol use in a young man. J Am Board Fam Med. 2009;22(2):197–201.PubMedCrossRefGoogle Scholar
  2. 2.
    Rosak J. U.S. regulators puzzled by Canada’s ruling on safety of ADHD drug. Psychiatric News. 2005;40(5):2.Google Scholar

References

  1. 1.
    ONTARGET Investigators, Yusef S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.CrossRefGoogle Scholar
  2. 2.
    Mann JF, Schmieder RE, McQueen M, et al (ONTARGET Investigators). Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind controlled trial. Lancet. 2008;372(9638):547–553.PubMedCrossRefGoogle Scholar
  3. 3.
    Taylor RB. The clinician’s guide to medical writing. New York: Springer, 2005; page 217.Google Scholar

Reference

  1. 1.
    Antoniou T, Gomes T, Juurlink DN, et al. Trimethoprim–sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin–angiotensin system. Arch Intern Med. 2010;170(12):1045–1049.PubMedCrossRefGoogle Scholar

References

  1. 1.
    Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf. 2004;13(7):417–426.PubMedCrossRefGoogle Scholar
  2. 2.
    ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574.CrossRefGoogle Scholar

References

  1. 1.
    Ridtitid W, Wongnawa M, Mahatthanatrakul W, Raungsri N, Sunbhanich M. Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. J Clin Pharm Ther. 2005;30:285–290.PubMedCrossRefGoogle Scholar
  2. 2.
    Sowunmi A, Adio RA, Oduola AM, Ogundahunsi OA, Salako LA. Acute psychosis after mefloquine: report of six cases. Trop Geogr Med. 1995;47(4):179–180.PubMedGoogle Scholar
  3. 3.
    Ridtitid W, Wongnawa M, Mahatthanatrakul W, Chaipol P, Sunbhanich M. Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol. 2000;52(10):1265–1269.PubMedCrossRefGoogle Scholar

References

  1. 1.
    Zapater P, Reus S, Tello A, Torrus D, Perez-Mateo M, Horga JF. A prospective study of the clarithromycin–digoxin interaction in elderly patients. J Antimicrob Chemother. 2002;50(4):601–606.PubMedCrossRefGoogle Scholar
  2. 2.
    Tanaka H, Matsumoto K, Ueno K, Kodama M, Yoneda K, Katayama Y, Miyatake K. Effect of clarithromycin on steady-state digoxin concentrations. Ann Pharmacother. 2003;37(2):178–181.PubMedCrossRefGoogle Scholar

Reference

  1. 1.
    Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008;300(4):395–404.PubMedCrossRefGoogle Scholar

References

  1. 1.
    Kloner RA, Hutter AM, Emmick JT, Mitchell ML, Denne J, Jackson G. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003;42(10):1855–1860.PubMedCrossRefGoogle Scholar
  2. 2.
    Tadalafil (Cialis). Epocrates Online. Available at: https://online.epocrates.com/u/10a3560?src=PK/. Accessed March 25, 2010.

Reference

  1. 1.
    de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics. 2005;46(3):262–273.PubMedCrossRefGoogle Scholar

Reference

  1. 1.
    Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281–288.PubMedCrossRefGoogle Scholar

References

  1. 1.
    Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Int Med. 2005;165:1095–1106.CrossRefGoogle Scholar
  2. 2.
    Ament PW, Bertolino JG, Liszewski JL. Clinically significant drug interactions. Am Fam Phys. 2000;61:1745–1754.Google Scholar
  3. 3.
    Gardner P, Phillips R, Shaughnessy AF. Herbal and dietary supplements: drug interactions in patients with chronic illnesses. Am Fam Phys. 2008;77(1):73–78.Google Scholar
  4. 4.
    Grant P. Warfarin and cranberry juice: an interaction? J Heart Valve Dis. 2004;13(1):25–26.PubMedGoogle Scholar
  5. 5.
    Suvarna R, Pirmohamed M, Henderson L. Possible interaction between warfarin and cranberry juice. BMJ. 2003;327(7429):1454.PubMedCrossRefGoogle Scholar
  6. 6.
    Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. Ann Pharmacother. 2004;38(1):50–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Schelleman H, Bilker WB, Brensinger CM, et al. Fibrate/statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med. 2010;123(2);151–157.PubMedCrossRefGoogle Scholar
  8. 8.
    Fischer HD, Juurlink DN, Mamdani MM, Koop A, Laupacis A. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med. 2010;170(7):617–621.PubMedCrossRefGoogle Scholar
  9. 9.
    Jiang X, Williams KM, Liauw WS, et al. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2004;57(5):592–599.PubMedCrossRefGoogle Scholar
  10. 10.
    Taylor RB. White coat tales – medicine’s heroes, heritage and misadventures. New York: Springer, 2008; page 62.Google Scholar

References

  1. 1.
    Andrén L, Andreasson A, Eggertsen R. Interaction between a commercially available St. John’s wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol. 2007;63(10):913–916.PubMedCrossRefGoogle Scholar
  2. 2.
    McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. CMAJ. 1996;155(3):293–295.PubMedGoogle Scholar
  3. 3.
    Gardner P, Phillips R, Shaughnessy AF. Herbal and dietary supplements: drug interactions in patients with chronic illnesses. Am Fam Phys. 2008;77(1):73–78.Google Scholar

References

  1. 1.
    Kale-Pradhan PB, Jassai HD, Wilhelm SM. Role of Lactobacillus in the prevention of antibiotic-associated diarrhea: a meta-analysis. Pharmacotherapy. 2010;30(2):119–129.PubMedCrossRefGoogle Scholar
  2. 2.
    Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21(5):583–590.PubMedCrossRefGoogle Scholar
  3. 3.
    Hickson M, D’Souza AL, Muthu N. Use of probiotic Lactobacillus preparation to prevent diarrhea associated the antibiotics: randomized double blind placebo controlled trial. BMJ. 2007;335(7610):80.PubMedCrossRefGoogle Scholar

References

  1. 1.
    Fuhr U. Drug interactions with grapefruit juice: extent, probable mechanism and clinical ­relevance. Drug Safety. 1998;18(4):251–272.PubMedCrossRefGoogle Scholar
  2. 2.
    Arayne MS, Sultana N, Bibi Z. Grapefruit juice–drug interactions. Pak J Pharm Sci. 2005;18(4):45–57.PubMedGoogle Scholar
  3. 3.
    Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice–drug interactions. Br J Clin Pharmacol. 1998;46(2):101–110.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Family Medicine School of MedicineOregon Health & Sciences UniversityPortlandUSA

Personalised recommendations